Table 2 STAT3 inhibitors in currently on-going clinical trials
Therapy | Type | Agent | Indication | Phase | NCT number | Ref |
|---|---|---|---|---|---|---|
Direct inhibitors | Small molecules | BBI608 (FDA approved) | Advanced malignancies | I/II | NCT01775423 | NA |
CRC | III | NCT01830621 | [117] | |||
Celecoxib* (FDA approved) | CRC | III | NCT00087256 | NA | ||
C188-9 | BC, CRC, HNSCC, HCC, NSCLC, GAC, Melanoma, Advanced cancer | I | NCT03195699 | NA | ||
OPB-111077 | Acute myeloid leukemia | I | NCT03197714 | NA | ||
Advanced HCC | I | NCT01942083 | NA | |||
OPB-31121 | Advanced cancer, Solid tumors | I | NCT00955812 | NA | ||
HCC | I/II | NCT01406574 | NA | |||
OPB-51602 | Malignant solid tumors | I | NCT01184807 | NA | ||
Hematological malignancies | I | NCT01344876 | NA | |||
Nasopharyngeal carcinoma | I | NCT02058017 | NA | |||
Pyrimethamine* (FDA approved) | CLL, Small lymphocytic lymphoma | I/II | NCT01066663 | NA | ||
Oligonucleotides | AZD9150 | Lymphoma | I/II | NCT01563302 | [118] | |
STAT3 decoy | Head and neck cancer | 0 | NCT00696176 | [119] | ||
Indirect inhibitors | JAK1/2 | AZD-1480 | Solid tumors | I | NCT01112397 | NA |
CYT 387 | Myelofibrosis | I/II | NCT01423058 | [120] | ||
PMF, Post-PV, Post-ET MF | III | NCT02101268 | NA | |||
Ruxolitinib (FDA approved) | Myelofibrosis | II | NCT03427866 | NA | ||
JAK2 | LY2784544 | Myeloproliferative neoplasms | II | NCT01594723 | [121] | |
SB1518 | Myelofibrosis | III | NCT02055781 | [122] | ||
EGFR | Cetuximab (FDA approved) | Metastatic CRC | I/II | NCT02117466 | NA | |
Panitumumab (FDA approved) | Advanced CRC | II | NCT03311750 | NA | ||
Metastatic CRC | IV | NCT02301962 | NA | |||
FGFR | Ponatinib (FDA approved) | CML | II | NCT04043676 | NA | |
CML, ALL | II | NCT04233346 | NA | |||
IL-6R | Siltuximab (FDA approved) | Multiple myeloma | II | NCT03315026 | NA | |
Tocilizumab (FDA approved) | HCC | I/II | NCT02997956 | NA | ||
VEGF | Bevacizumab (FDA approved) | Metastatic CRC | II | NCT02226289 | NA | |
VEGFR | Apatinib | Lung carcinoma | II | NCT03709953 | NA | |
VEGFR, PDGFR | Sorafenib (FDA approved) | Advanced HCC | IV | NCT02733809 | NA | |
VEGFR, PDGFR, c-KIT | Sunitinib (FDA approved) | Clear cell renal carcinoma | II | NCT03066427 | NA | |
Pancreatic neuroendocrine tumor metastatic | II | NCT02713763 | NA | |||
SRC, ABL | Dasatinib (FDA approved) | Chronic-phase CML | IV | NCT01660906 | [123] | |
SRC | Bosutinib (FDA approved) | CML | II | NCT02810990 | NA | |
KX2-391 | Bone-metastatic, Castration-resistant PCa | II | NCT01074138 | [124] | ||
Combination | Direct inhibitors and ICB | AZD9150, Durvalumab (anti-PD-L1) | NSCLC | II | NCT03334617 | NA |
PC, CRC, NSCLC | II | NCT02983578 | NA | |||
Advanced solid tumors, Metastatic HNSCC | I/II | NCT02499328 | NA | |||
Diffuse large B-cell lymphoma | I | NCT02549651 | NA | |||
BBI608, Nivolumab (anti-PD-L1) | Metastatic CRC | II | NCT03647839 | NA | ||
BBI608, Pembrolizumab (anti-PD-1) | Metastatic CRC | I/II | NCT02851004 | NA | ||
Indirect inhibitors and ICB | Apatinib, SHR-1210 (anti-PD-1) | Melanoma | II | NCT03955354 | NA | |
Bevacizumab, Atezolizumab (anti-PD-L1) | Unresectable HCC | III | NCT03434379 | [125] | ||
Cetuximab, Pembrolizumab (anti-PD-1) | Recurrent or metastatic HNSCC | II | NCT03082534 | NA | ||
Dasatinib, Ipilimumab (anti-CTLA-4) | GIST, Stage III /IV soft tissue sarcoma | I | NCT01643278 | [126] | ||
Dasatinib, Nivolumab (anti-PD-L1) | Philadelphia chromosome positive ALL | I | NCT02819804 | NA | ||
Ruxolitinib, Pembrolizumab (anti-PD-1) | Hematological malignancies | II | NCT04016116 | NA | ||
Metastatic stage IV TNBC | I | NCT03012230 | NA | |||
Sorafenib, BGB-A317(anti-PD-1) | HCC | III | NCT03412773 | NA | ||
Sorafenib, Nivolumab (anti-PD-L1) | Advanced or metastatic HCC | II | NCT03439891 | NA | ||
Indirect inhibitor and CAR-T | Tocilizumab, CAR-T 19 | Lymphoblastic leukemia | NA | NCT02906371 | NA |